Clinical Trial Update: Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation [Phase 2]

View source ↗

Summary

Phase 2 study assessing the effect of ivacaftor (VX-770) on hyperpolarized Helium-3 MRI markers in cystic fibrosis patients with the G551D CFTR mutation; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Kalydeco (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2014-07-31